{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:08:05Z","timestamp":1758636485413},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/ftd.0000000000000210","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T10:55:33Z","timestamp":1427280933000},"page":"745-750","source":"Crossref","is-referenced-by-count":5,"title":["High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1\u2013Infected Patients"],"prefix":"10.1097","volume":"37","author":[{"given":"Karin","family":"Lindahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"H\u00f6rnfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"St\u00e5hle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sa","family":"Parke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schvarcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":". Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":". Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mcp.2002.127112","article-title":". Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.","volume":"72","author":"Jen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2893.2003.00475.x","article-title":". Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.","volume":"11","author":"Lindahl","year":"2004","journal-title":"J Viral Hepat"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1208\/s12248-012-9368-z","article-title":". Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.","volume":"14","author":"Jin","year":"2012","journal-title":"AAPS J"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","article-title":". Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.","volume":"24","author":"Bruchfeld","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":". High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":". Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":". Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":". Telaprevir for retreatment of HCV infection.","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1021\/mp200647a","article-title":". Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(--) mice.","volume":"9","author":"Moss","year":"2012","journal-title":"Mol Pharm"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockroft","year":"1976","journal-title":"Nephron"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/(SICI)1096-9071(199607)49:3<155::AID-JMV1>3.0.CO;2-3","article-title":". Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences.","volume":"49","author":"Yun","year":"1996","journal-title":"J Med Virol"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.21712","article-title":". Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.","volume":"46","author":"Shiffman","year":"2007","journal-title":"Hepatology"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":". Antiviral action of ribavirin in chronic hepatitis C.","volume":"126","author":"Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2893.2012.01587.x","article-title":". Concentration guided ribavirin dosing with darbepoetin support and Peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation.","volume":"19","author":"Ackefors","year":"2012","journal-title":"J Viral Hepat"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:29:36Z","timestamp":1620952176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201512000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000210","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}